Melatonin Prescription in Children and Adolescents in Relation to Body Weight and Age

Kimland, Elin; Dahlén, Elin; Martikainen, Jari; Célind, Jimmy; Kindblom, Jenny M.

doi:10.3390/ph16030396

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the United Kingdom melatonin is only available via prescription. Within Europe, the lack of harmonisation in the provision of melatonin provision leads to variability in its regulatory status (i.e., OTC vs. prescription) from country to country[ 25 , 26 ], thus requiring varying levels of pharmacist involvement in its provision.…”

Section: Methodsmentioning

confidence: 99%

Pharmacists’ perspectives and attitudes towards the 2021 down-scheduling of melatonin in Australia using the Theoretical Domains Framework: a mixed-methods study

et al. 2023

View full text Add to dashboard Cite

Background In Australia, prescription melatonin became a ‘Pharmacist Only Medicine’ for people over 55 with insomnia from June 2021. However, little is known about pharmacists’ views on melatonin down-scheduling and perceived impacts on practice. Aim To explore Australian community pharmacists’ views on and attitudes towards the down-scheduling of melatonin. Method A convenience sample of community pharmacists and pharmacy interns were recruited. Participants completed a survey capturing demographic and professional practice details, and rated their knowledge, beliefs and attitudes towards melatonin. This was followed by an online semi-structured interview. Interviews were guided by a schedule of questions developed using the Theoretical Domains Framework and explored the perceived role of melatonin, preparation/response to down-scheduling, practice changes and patient interactions. Interviews continued until data saturation and were digitally recorded, transcribed verbatim and analysed using the Framework Approach. Results Twenty-four interviews were conducted with community pharmacists (n = 19) and intern pharmacists (n = 5), all practicing in metropolitan areas. Pharmacists/intern pharmacists welcomed the increased accessibility of melatonin for patients. However, pharmacists perceived a disconnect between the guidelines, supply protocols and pack sizes with practice, making it difficult to monitor patient use of melatonin. The miscommunication of eligibility also contributed to patient-pharmacist tension when supply was denied. Importantly, most participants indicated their interest in upskilling their knowledge in melatonin use in sleep, specifically formulation differences and dosage titration. Conclusion While pharmacists welcomed the down-scheduling of melatonin, several challenges were noted, contributing to pharmacist-patient tensions in practice. Findings highlight the need to refine and unify melatonin supply protocols and amend pack sizes to reflect guideline recommendations as well as better educating the public about the risk-benefits of melatonin.

show abstract

Section: Methodsmentioning

confidence: 99%